| 摘要: |
| 目的：分析2017版医保药品目录限定支付情况。方法：通过归纳分析、对比分析等方法总结限定支付类型并分析所涉及的药品在数目、类别、适应症等方面的特征。结果：2017版医保药品目录对903个品种实行限定支付，包括险种限制、统筹基金使用范围限制、二线用药限制和适应症限制等，各限制具体情况体现2017版目录“宽进严管理”的调整思路。结论：2017版目录的限定较为规范，理论上保证了临床的合理用药和医保基金的高效使用。 |
| 关键词: |
| DOI： |
|
| 基金项目: |
|
| Analysis on Reimbursement Limits of National Basic Medical Insurance Drug List 2017 |
|
| () |
| Abstract: |
| Objective: Analyzing reimbursement limits of national basic medical insurance drug list 2017. Methods: The kinds of reimbursement limits and characters of relative drugs in quantities, categories and indications are concluded through methods of induction and correlation . Results: 903 drugs are limited in national basic medical insurance drug list 2017, the limits involve categories of insurance, serviceable range of pooling funds，second-line use and indications. Conclusion: the reimbursement limits are normative, ensuring rational drug use and efficiency of medical insurance funds. |
| Key words: |
